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ABSTRACT
Background: Interferon (IFN)-α is the only approved
treatment for chronic hepatitis C. Interstitial pneu-
monia and, rarely, exacerbation of bronchial asthma
have been reported as adverse pulmonary effects of
IFN-α treatment. The purpose of the present study was
to clarify whether IFN-α treatment affects pulmonary
function and airway responsiveness in patients with
chronic hepatitis C.
Methods: We studied 17 patients (nine males and
eight females; mean age 46 years; range 30–62 years)
with chronic active hepatitis C diagnosed by serum tests
and liver biopsy. Pulmonary function tests included vital
capacity (VC), forced expiratory volume in 1 s (FEV1),
forced expiratory flow in the middle half of the forced
vital capacity (FVC25–75%), total lung capacity and
carbon monoxide diffusing capacity of the lung (DLCO),
which was adjusted for hemoglobin concentration.
Airway responsiveness was measured by methacholine
inhalation challenge and determination of the provoc-
ative concentration of methacholine causing a 20% fall
in FEV1 (PC20). These tests were performed before and 
3 months after initiation of IFN-α therapy.
Results: No patient developed interstitial pneumonia,
although there was a tendency for the hemoglobin-
adjusted DLCO to decrease. Other pulmonary function
test parameters were not affected. Overall, there was
no significant change in PC20 (from 15.0 to 11.4 mg/
mL). In three patients whose initial PC20 was within 
the normal range, airway hyperresponsiveness was
induced and one patient developed bronchial asthma
after IFN-α therapy.
Conclusions: These findings suggest that IFN-α induces
airway hyperresponsiveness to methacholine in a few
patients with chronic hepatitis C.
Key words: airway responsiveness, carbon monoxide
diffusing capacity, chronic hepatitis C, interferon-α,
methacholine, pulmonary function.
INTRODUCTION
Infection with hepatitis C virus (HCV) is the most common
cause of chronic viral hepatitis worldwide and 20–30% 
of patients develop liver cirrhosis or hepatocellular car-
cinoma. Interferon (IFN)-α is widely used as the only
approved therapy for chronic hepatitis C.1 Although the
rate of the long-term or sustained response, in which
serum aminotransferase is normal and no HCV-RNA is
detectable after the cessation of therapy, is only 15–25%,
IFN-α therapy usually leads to rapid eradication of
viremia. The side effects of IFN include an influenza-like
reaction with fever and chills, proteinuria, bone marrow
suppression, fatigue, depression, alopecia and autoim-
mune diseases, such as various thyroid disorders.2 As an
adverse pulmonary effect, a number of cases of interstitial
pneumonia or pneumonitis have been reported.3–5 The
characteristic clinical features of interstitial pneumonia
include respiratory symptoms, such as fever, dyspnea 
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and cough, diffuse reticular interstitial infiltrates on chest
X-rays, restrictive impairment with reduced diffusion
capacity on pulmonary function testing and arterial
hypoxemia. Discontinuation of IFN with occasional corti-
costeroid use leads to resolution in most cases.
Monitoring of pulmonary function testing, especially dif-
fusion capacity, has been used for the diagnosis of
drug-induced interstitial pneumonia at an early stage.
Recently, exacerbation of bronchial asthma has been
reported as a new side effect of IFN-α therapy.6 Two
patients developed severe exacerbation of asthma, which
resolved promptly following discontinuation of IFN and
the use of corticosteroid therapy. However, it is not known
whether IFN-α induces bronchial asthma or airway
hyperresponsiveness (AHR), which is a characteristic phe-
nomenon and mostly attributable to airway inflammation
of asthma, in patients without underlying asthma.
In the present study, we investigated the effects of
IFN-α therapy on pulmonary function and airway res-
ponsiveness in patients with chronic hepatitis C.
METHODS
Subjects
Seventeen patients (nine males and eight females; mean
age 46 years; range 30–62 years) with chronic hepatitis
C diagnosed by elevated serum aminotransferase con-
centrations, anti-HCV and HCV-RNA in the serum and
chronic active hepatitis on liver biopsy, were enrolled in
the study. There were nine smokers, three ex-smokers and
five subjects who had never smoked. Two patients had
seasonal rhinitis and one had diabetes mellitus, but none
had bronchial asthma or chest X-ray abnormalities.
Six million units natural IFN-α every day for 2 weeks and
three times a week for 6 months was given intramuscularly.
Pulmonary function and airway responsiveness were mea-
sured before and 3 months after initiation of treatment. No
patients were receiving Chinese herbal medicine or any
medication known to affect airway tone or responsiveness.
None had respiratory complaints or findings of pulmonary
infections during the 2 months prior to each testing day. 
If an abnormal change in each parameter was found, 
the parameter was followed up after 6 months treatment.
Patients exhibiting a long-term or sustained response (nor-
malization of the serum aminotransferase and undetect-
able HCV-RNA for at least 6 months after the cessation of
IFN therapy) were identified as IFN-α responders.
Informed consent was obtained from all patients prior
to the study.
Pulmonary function testing
Spirometry and diffusing capacity were determined using
computerized equipment (model CHESTAC-33; CHEST
MI, Tokyo, Japan). The vital capacity (VC), forced expira-
tory volume in 1 s (FEV1), forced expiratory flow in the
middle half of the forced vital capacity (FVC25–75%) and 
total lung capacity (TLC) were determined according to
standard techniques. The carbon monoxide diffusing
capacity of the lung (DLCO) was measured by the single
breath method and was adjusted for hemoglobin (Hb)
concentration according to the following equation of 
Cotes et al.:7
Values for pulmonary function tests are expressed as a
predicted percentage.
Airway responsiveness
Bronchial challenge tests to methacholine were per-
formed with a DeVilbiss nebulizer (model 646; DeVilbiss
Health Care, Somerset, PA, USA) driven by compressed
air at a flow rate of 5 L/min according to the standard
method proposed by the Japanese Society of Allergology
in 1982.8,9 Briefly, after baseline spirometry and inhala-
tion of physiologic saline, patients inhaled aerosols from
solutions of doubling doses of methacholine at concen-
trations of 0.078, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 
10 and 20 mg/mL. The aerosols were inhaled by tidal
breathing for 2 min and FEV1 was measured immediately
after each inhalation. The tests were discontinued 
when FEV1 decreased by more than 20% compared with
the baseline value or when the highest concentration 
(20 mg/mL) was reached. The provocative concentration
of methacholine causing a 20% fall in FEV1 was cal-
culated as PC20. A PC20 value ≤ 10 mg/mL was defined
as AHR.10,11
Statistical analysis
Results are expressed as the mean±SD for VC, FEV1,
FVC25–75% , TLC and Hb-adjusted DLCO. The PC20 values
are expressed as the geometric mean±SD. Statistical
analysis was performed using the Wilcoxon signed ranks
test. P < 0.05 was considered significant.
Hb-adjusted DLCO (males) = observed DLCO (10.22 + Hb)
1.7 Hb
Hb-adjusted DLCO (females) = observed DLCO (9.38 + Hb)
1.7 Hb
RESULTS
Although all patients complained of influenza-like symp-
toms and fatigue after IFN-α therapy had been initiated,
these side effects were mild and no patient developed
interstitial pneumonia. Five of 17 patients (29%) were
found to be IFN-α responders, in whom a long-term or
sustained response to IFN therapy was achieved.
Table 1 shows the changes in pulmonary function tests
before and during treatment. There was a tendency for
the Hb-adjusted DLCO (P = 0.07) to decrease from 118
± 19 to 108 ± 17%, although each value was within the
normal range. No other pulmonary function parameters
were affected.
The changes in the PC20 of methacholine are shown 
in Fig. 1. There was no significant change between
before and during therapy in PC20 values overall (15.0
vs 11.4 mg/mL; P = 0.14). However, three of 17
patients (18%) with PC20 > 10 mg/mL at baseline devel-
oped new AHR without asthma-like symptoms. Table 2
summarizes the characteristics of three patients, one
male and two females, consisting of one responder and
two non-responders to IFN therapy. Although patient 2
had a history of seasonal rhinitis, each methacholine
challenge test was performed out of season and he was
asymptomatic. Patient 2 was also a current smoker, but
his smoking habit had not changed during therapy.
Patients 1 and 2 still showed AHR after the cessation of
IFN therapy and patient 2 developed bronchial asthma
thereafter. His asthma severity was mild intermittent,
requiring a short-acting inhaled β2-adrenergic receptor
agonist on an as-needed basis. However, the PC20 of
patient 3 returned to normal after IFN therapy. The FEV1
values of the three patients had not changed during
IFN therapy and the follow-up periods. There were no
differences between these three patients and the other
14 patients with regard to the clinical features of chronic
hepatitis C, including age, duration of disease, the
serum level or genotype of HCV-RNA, histologic findings
and cumulative IFN dose or pattern of response to
therapy. The PC20 value of the patient with AHR before
therapy was still below the normal level during therapy,
but she remained asymptomatic.
DISCUSSION
The present study shows that AHR to methacholine was
induced in three of 17 patients (18%) with chronic hepati-
tis C but without asthma or other respiratory disease 
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Table 1 Changes in pulmonary function tests before and
during interferon treatment
Pretreatment During treatment P
VC 106 ± 12 105 ± 16 0.60
FEV1 102 ± 12 98 ± 13 0.13
FEF25–75% 96 ± 20 92 ± 20 0.34
TLC 112 ± 10 109 ± 9 0.45
DLCO* 118 ± 19 108 ± 17 0.07
Data are the mean±SD of the predicted percentage.
*Adjusted for hemoglobin concentration.
VC, vital capacity; FEV1, forced expiratory volume in 1 s; FEF, forced
expiratory flow in the middle half of the forced vital capacity; TLC, total
lung capacity; DLCO, carbon monoxide diffusing capacity of the lung.
Fig. 1 Changes in PC20 of methacholine (mg/mL) before 
and during interferon (IFN)-α treatment. Although there was 
no significant change overall, a decrease from the normal 
to the abnormal range in PC20 was found in three patients. 
One patient with seasonal rhinitis had airway hyperresponsive-
ness before treatment, but no change was observed during
treatment.
3 months after IFN-α therapy had been initiated.
Although the cumulative dose or duration of IFN therapy
and having no asthmatic symptoms were common
among the three patients, it is unlikely that the induction
of AHR was associated with the patients’ characteristics,
the serum level or genotype of HCV-RNA or the response
to IFN therapy. Furthermore, the follow-up study revealed
the diversity of prognosis of the three patients who
acquired AHR; two still had AHR after the cessation of IFN
therapy, one of whom developed mild intermittent
asthma thereafter and one remained asymptomatic,
while the other patient’s airway responsiveness returned
to normal.
When interpreting PC20 results for an individual
patient, several factors that will worsen or improve AHR
should be taken into consideration. Concerning the
quality of the patient’s spirometry maneuvers, there were
no changes in FEV1 when testing each PC20 value in all
three patients. Short-term within-subject repeatability
studies when patients are in a stable clinical state show
that the 95% confidence intervals for repeat determina-
tions of methacholine PC20 lie within ± 1.5 doubling
doses.12 However, in the three patients in the present
study, the changes in PC20 exceeded 1.5 doubling doses
either during the IFN therapy or during the follow-up
periods compared with baseline PC20 values. Atopy is
also an important factor for AHR. Because methacholine
challenges were performed out of season in patient 2,
who had a history of seasonal rhinitis, the effect of recent
antigen exposure was suggested to be excluded. Further-
more, although patient 2 was a current smoker, it was
unlikely that his smoking habit induced new AHR after
only a 3 month interval because he showed no baseline
airway obstruction and his airway caliber, measured as
the FEV1, had not changed. Therefore, we cannot explain
the induction of AHR in our patients by the known factors
that affect the PC20 value of methacholine as stated
above. It is suggested that new AHR was induced by IFN
therapy.
The interpretation of the induction of AHR within non-
asthmatic patients is complex because of the lack of
information and it must be undertaken with caution.
Kennedy et al. reported a significant increase in AHR
during a 2 year follow up among apprentices exposed to
metalworking fluids.13 In the study of Kennedy et al.,13
new AHR (baseline PC20 > 8 mg/mL and follow-up PC20
≤ 8 mg/mL methacholine) was induced in four of 157
control subjects (3%), some of whom had atopy or a
smoking habit, but no underlying asthma. Compared
with the incidence rate of new AHR in that study, the rate
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Table 2 Characteristics of three patients who acquired new airway hyperresponsiveness
Patient
1 2 3
Age (years) 45 59 62
Gender Female Male Female
Response to the IFN-α therapy Responder Non-responder Non-responder
Smoking habit Never smokee Current smoker Ex-smoker
Coexisting disease – Seasonal rhinitis –
Allergic status Non-atopic Atopic Non-atopic
WBC (/µL) 6700 5100 5500
% Eosinophils 0 0 4
Total IgE (U/mL) < 5 2300 210
Specific IgE to common inhalant allergens Negative Timothy, Ragweed Negative
PC20 (mg/mL)
Before therapy 17.8 11.0 > 20.0
After initiation of therapy 5.2 4.8 5.6
1 year follow up 4.0 3.4 12.0
FEV1 (L)
Before therapy 2.30 2.07 1.70
After initiation of therapy 2.30 2.06 1.72
1 year follow up 2.26 2.00 1.78
Subsequent development of asthma – + –
IFN, interferon; WBC, white blood cells; FEV1, forced expiratory volume in 1 s.
in the present study of three of 17 patients (18%) is
higher, although there are several differences between
the two studies and a simple comparison is difficult.
Possible explanations for the normalization of PC20 in
patient 3 after the cessation of IFN therapy may be as
follows. One is that the effect of IFN on her airway respon-
siveness may be limited to only during therapy, in contrast
with the two other patients, who acquired a long-lasting
effect on their airway responsiveness, suggesting a diver-
sity of each patient’s response to IFN. Another explanation
is that her decrease in PC20 during the IFN therapy may 
be false positive due to errors such as diluting metha-
choline solutions. Indeed, this false positive result may
have occurred, but the change in PC20 in patient 3 during
IFN therapy increased beyond the repeatability range of
± 1.5 doubling doses, as reported previously.12 Therefore,
the former explanation is suggested as more possible.
The present study also showed that the Hb-adjusted
DLCO tended to decrease 3 months after IFN-α therapy
had been initiated. It has been reported that interstitial
pneumonia induced by IFN-α typically occurrs between 
8 and 12 weeks after the initiation of therapy,2 suggesting
the possibility that IFN-α therapy may induce subclinical
changes, leading to the onset of interstitial pneumonia.
However, those changes were within the normal range
and actually no patients developed interstitial pneumonia
in the present study. No other parameters were affected
during therapy, as reported previously.14 The incidence
rate of interstitial pneumonia is estimated to be 0.1%15
and that of exacerbation of bronchial asthma is extreamly
low. As long as IFN therapy remains effective and useful, it
should be elucidated what predisposing factors cause
these adverse pulmonary effects to occur in such a small
proportion of susceptible patients with chronic hepatitis C.
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